Boston Scientific Corporation vs Eaton Corporation plc — how do they compare? Boston Scientific Corporation trades at $42.53 (market cap $66.37B), while Eaton Corporation plc trades at $412 (market cap $161.35B). The key difference: Eaton Corporation plc is far larger — about 2.4× Boston Scientific Corporation's market cap, and Eaton Corporation plc pays a 1.06% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | ETN | |
|---|---|---|
Market Cap | $66.37B | $161.35B |
Sector | Health | Technology |
52-Week High | $108.14 | $435.78 |
52-Week Low | $42.63 | $315.82 |
Enterprise Value | $75.94B | $182.43B |
Dividend Yield | — | 1.06% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Eaton Corporation (ETN) trades at $402.85, down 1.09% on the day, with a bearish technical signal from moving averages. The stock exhibits strong fundamentals, including a 13.99% net income margin and consistent quarterly earnings beats, most recently in Q1 2026. Recent news highlights growth in data center and aerospace markets, supported by strategic acquisitions and a $2.1 billion R&D investment in 2025.
The outlook remains positive, driven by robust analyst sentiment with a $449.50 consensus price target and no sell ratings. Key opportunities include exposure to high-growth infrastructure and AI-related power demand. Risks involve elevated valuation multiples, such as a P/E of 40.66, and potential execution challenges from recent investments, with Q2 2026 earnings on July 31, 2026, serving as a near-term catalyst.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →